Skip to content

Trial · Interventional

CompletedPhase 4Registry data

Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic Surgery

NCTNCT06201819 (opens ClinicalTrials.gov in a new tab)Other idCEI-008-20161212
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Phase 4
Enrollment
37 participants (actual)
Sponsor
Hospital Civil Juan I. Menchaca · Other
Design
Allocation not applicable · Open label (no masking)
Countries
1 country

Mexico

Start
18 Dec 2022
Primary completion
18 Mar 2023
Completion
1 May 2023
First posted
11 Jan 2024
Last update posted
18 Jan 2024
Conditions
Weight Loss · Bariatric Surgery Candidate · Obesity, Morbid

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
202220232024
  1. Ph 4

    Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic Surgery

    NCT06201819

    18 Dec 2022 to 1 May 2023

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

Severe obesity is associated with considerable reduction of wellbeing and life expectancy. People living with severe obesity tend to die 8 to 10 years earlier. Preoperative management of patients living with severe obesity can be challenging and proper weight-loss may help obtain better outcomes and less morbidity. The effectiveness of GLP-1 analogue Liraglutide in preoperative weight-loss was evaluated in the study.

Interventions

  • Liraglutide injectionDrug

Arms1

  • Experimental

    Patients with morbid obesity in bariatric surgery preparation protocol

    All patients with body mass index \>48 kg/m2 in preoperative protocol for bariatric surgery using liraglutide for preoperative weight loss

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Preoperative weight changes

    Time frame · 3 months

    Registry description

    Total body weight change during the drug administration

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Patients with BMI greater than 48 kg/m2 in pre-surgical protocol for bariatric surgery of the Bariatric and Metabolic Surgery Unit of the Civil Hospital of Guadalajara "Dr. Juan I. Menchaca Exclusion Criteria: * Patients under 18 years of age or over 65 years of age. * Pregnant patients. * Patients who do not agree to give their consent and take part in the study. * Patients with allergy to liraglutide, multiple endocrine neoplasia type 2 and medullary thyroid cancer, gallstones. Removal: * Patients who decide to abandon the study. * Patients who do not follow the instructions or do not adhere to the treatment.

PepBank is a research reference. Talk to a doctor before you use any peptide.